Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06054464 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants

A Phase 1 study, sponsored by PMV Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
28
Enrollment target

NCT06054464: Completed Phase 1 study, sponsored by PMV Pharmaceuticals.

NCT06054464 is a Phase 1 study that has completed, run by PMV Pharmaceuticals. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06054464, a Phase 1 study, has completed, sponsored by PMV Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
28 participants
Enrollment target

Study Summary

This study will assess the effect of a Proton Pump Inhibitor (PPI) (rabeprazole) on the pharmacokinetics (PK) of PC14586 and the effect of an H2-receptor antagonist (famotidine) on the PK of PC14586

Primary Outcome

Determine the Cmax of PC14586 when co-administered with rabeprazole in plasma.

Interventions

  • DRUG Rabeprazole
  • DRUG Famotidine
  • DRUG PC14586

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2023-09-19
Est. Completion 2024-02-06
Phase Phase 1
PMV Pharmaceuticals

6 total trials

What the finished NCT06054464 record still lists

NCT06054464 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).

The record links to 0 conditions, and to 3 interventions - of which Rabeprazole is the first listed.

NCT06054464 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06054464 about?

NCT06054464 is a clinical study titled "A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants". This study will assess the effect of a Proton Pump Inhibitor (PPI) (rabeprazole) on the pharmacokinetics (PK) of PC14586 and the effect of an H2-receptor antagonist (famotidine) on the PK of PC14586

What is the current status of trial NCT06054464?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2023-09-19. Estimated completion is 2024-02-06.

What interventions are being tested in trial NCT06054464?

The interventions under investigation include: Rabeprazole (DRUG), Famotidine (DRUG), PC14586 (DRUG).

Who is sponsoring clinical trial NCT06054464?

This trial is sponsored by PMV Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06054464's enrollment target sits among peer trials

28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06054464, the US trial registry maintained by the National Library of Medicine. NCT06054464 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.